SCHEMBL10327132

SCHEMBL10327132

CC(C)C1CCC(OCC2CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 20/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13115124 0.88 HCRTR2 (0.39) HCRTR2
SCHEMBL26726421 0.81 HRH3 (0.42) HCRTR2
SCHEMBL31093863 0.81 — —
SCHEMBL26362569 0.81 CTSL (0.41) —
SCHEMBL4762344 0.79 HCRTR2 (0.38) HCRTR2
SCHEMBL11991405 0.79 HCRTR2 (0.38) HCRTR2
SCHEMBL11883250 0.78 HCRTR2 (0.30) HCRTR2
SCHEMBL23945712 0.78 JAK2 (0.33) HCRTR2
SCHEMBL9066827 0.78 HCRTR2 (0.39) HCRTR2
SCHEMBL6683115 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 — — US disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 — — US disclosed
WO-2021138434-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-07-08 — — WO disclosed
US-8791303-B2 Herbicides SYNGENTA LIMITED (GB) 2014-07-29 — — US disclosed
US-8791303-B2 Herbicides SYNGENTA LIMITED (GB) 2014-07-29 — — US disclosed
US-20120178623-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-07-12 — — US disclosed
US-20120178623-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 HCRTR2 3519/4885
US-20120178623-A1 NOVEL HERBICIDES DDT, CBR3, C9 HCRTR2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback